David G. Brachman, MD, FASTRO
Co-Founder and Chief Technology Officer
Dr Brachman was instrumental in the development of GammaTile Therapy. He is a
cofounder and the chief technology officer of GT Medical Technologies, as well as an
inventor on all the company’s 25+ granted patents.
Dr Brachman is board certified in Internal Medicine and in Radiation Oncology. After
serving as in Internist in the US Public Health Service he re-trained in Radiation
Oncology at the University of Chicago, becoming an Assistant Professor in Radiation
and Cellular Oncology before relocating to The Barrow Neurologic Institute in Phoenix.
After more than 15 years as the Chairman and Medical Director of the Radiation
Oncology Department and Co-director of the GammaKnife and CyberKnife programs he
retired from The Barrow Neurological Institute to help advance the GammaTile effort.
His radiation oncology background includes appointment as Professor of Radiation
Oncology at the University of Arizona College of Medicine – Phoenix, and more than 15
years as a member of the NCI-sponsored Radiation Therapy Oncology Group CNS
Tumor Steering Committee. Dr Brachman is known for his extensive neuro-oncology
clinical trials expertise and been an author on more than 60 peer-reviewed publications.
His publishing credits include The Lancet, The New England Journal of Medicine, and
Cancer Research on work that advanced our fundamental of tumors as well as patient
standards of care.